PHIO PHARMACEUTICALS CORP. Investment Income, Net
PHIO PHARMACEUTICALS CORP. (PHIO) reported Investment Income, Net of $130.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-06
- PHIO PHARMACEUTICALS CORP. investment income, net for the quarter ending 2026-06-30 was $130.00K, a 9.09% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. investment income, net for the quarter ending 2026-03-31 was $161.00K, a 28.80% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. investment income, net for the quarter ending 2025-12-31 was $163.00K, a 288.10% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. investment income, net for the quarter ending 2025-09-30 was $113.00K, a 71.21% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. investment income, net for fiscal 2025 was $520.00K, a 125.11% increase from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. investment income, net for fiscal 2024 was $231.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $130.00K 10-Q · filed 2026-08-06 | $291.00K 10-Q · filed 2026-08-06 | $454.00K derived: sum of 3 quarters · filed 2026-08-06 | $567.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $161.00K 10-Q · filed 2026-05-07 | $324.00K derived: sum of 2 quarters · filed 2026-05-07 | $437.00K derived: sum of 3 quarters · filed 2026-05-07 | $580.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $276.00K derived: sum of 2 quarters · filed 2026-03-05 | $419.00K derived: sum of 3 quarters · filed 2026-08-06 | $520.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $113.00K 10-Q · filed 2025-11-13 | $256.00K derived: sum of 2 quarters · filed 2026-08-06 | $357.00K 10-Q · filed 2025-11-13 | $423.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $143.00K 10-Q · filed 2026-08-06 | $246.00K 10-Q · filed 2026-08-06 | $310.00K derived: sum of 3 quarters · filed 2026-08-06 | $376.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $125.00K 10-Q · filed 2026-05-07 | $167.00K derived: sum of 2 quarters · filed 2026-05-07 | $233.00K derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $108.00K derived: sum of 2 quarters · filed 2026-03-05 | $231.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $66.00K 10-Q · filed 2025-11-13 | $189.00K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |